China, Alzheimer's disease

Eli Lilly's Alzheimer's treatment approved in China (Dec. 17)
(Corrects paragraph 8 of Dec. 17 story to reflect that the EU regulator reversed its July decision in November to recommend approval for Biogen's drug, Leqembi) (Reuters) -China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's,
Lilly's Alzheimer's drug Kisunla is cleared in China
China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there almost a year after Eisai and Biogen's anti-amyloid rival Leqembi (lecanemab), which was cleared by the NMPA in January.
China Approves Lilly's Kisunla For Early Symptomatic Alzheimer's Disease Treatment
Eli Lilly and Co. (LLY) said that the National Medical Products Administration (NMPA) in China has approved Kisunla (donanemab-azbt,
Eli Lilly’s Kisunla Approved in China, Paving the Way for Innovative Alzheimer’s Treatment Options
China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a
Global Health Advancements: Eli Lilly's Alzheimer's Treatment Gains Ground
The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in China, Merck's deal with Hansoh for a new obesity drug, impending HIV medication availability,
Eli Lilly's Alzheimer's treatment approved in China
China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January, the company said late on Tuesday.
Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion),
Lilly's Kisunlatm (Donanemab-Azbt) Approved In China For The Treatment Of Early Symptomatic Alzheimer's Disease
KisunlaTM (donanemab-azbt) , pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
The Pharma Letter3d
Lilly and Innovent to commercialize Jaypirca in China
Eli Lilly and Innovent Biologics partner on the distribution and promotion of Jaypirca in China, the first non-covalent BTK ...
Business Insider2d
Eli Lilly’s Kisunla approved in China for Alzheimer’s Disease treatment
The company states: “Eli Lilly (LLY) announced that the National Medical Products Administration in China has approved Kisunla, an Alzheimer’s treatment for adults with early symptomatic ...
24/7 Wall St1d
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...